Transamerica Financial Advisors Inc. Has $59,000 Stock Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Transamerica Financial Advisors Inc. increased its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 1,506.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 257 shares of the medical research company’s stock after purchasing an additional 241 shares during the period. Transamerica Financial Advisors Inc.’s holdings in Laboratory Co. of America were worth $59,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Graney & King LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter valued at about $26,000. Fortitude Family Office LLC lifted its holdings in shares of Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Geneos Wealth Management Inc. grew its position in Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 127 shares during the period. Human Investing LLC acquired a new stake in Laboratory Co. of America in the 4th quarter valued at $39,000. Finally, True Wealth Design LLC increased its stake in Laboratory Co. of America by 3,660.0% during the 3rd quarter. True Wealth Design LLC now owns 188 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 183 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the sale, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $235,000.00. Following the completion of the transaction, the director now owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. This trade represents a 7.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,500 shares of company stock valued at $3,577,572 over the last three months. 0.85% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on LH. Bank of America raised their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Citigroup raised shares of Laboratory Co. of America from a “neutral” rating to a “buy” rating and raised their price target for the company from $250.00 to $300.00 in a research report on Tuesday, March 4th. Piper Sandler boosted their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their target price for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Finally, Jefferies Financial Group upped their price target on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $269.92.

Laboratory Co. of America Stock Performance

Shares of LH stock opened at $229.75 on Monday. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $258.59. The firm’s 50-day simple moving average is $244.80 and its two-hundred day simple moving average is $234.69. The firm has a market cap of $19.23 billion, a price-to-earnings ratio of 26.05, a P/E/G ratio of 1.71 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, equities analysts forecast that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.